While cost discipline improved financials, the delay in NMRA-215 due to toxicology concerns introduces pipeline risk. Investors should monitor the Q2 2026 readouts for navacaprant and NMRA-898, which are key near-term catalysts. The strong cash position reduces near-term dilution risk.
NMRA drugs
NMRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $1.93entry
- T+1 · 8mo ago +1.04%α −1.85% · $1.95
- T+5 · 7mo ago +10.36%α +6.06% · $2.13
- T+20 · 7mo ago +16.58%α +3.98% · $2.25
- T+60 · 5mo ago −21.76%α −38.25% · $1.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a narrower net loss compared to the prior year. The company highlighted clinical progress across its pipeline, including new Phase 1b data for NMRA-511 in Alzheimer’s agitation, full enrollment in the KOASTAL-2 and -3 trials for navacaprant, and advancement of NMRA-898 as the lead M4 program in schizophrenia. With $182.5 million in cash, Neumora expects to fund operations into Q3 2027.
Key Financial Metrics
Key Facts
- Neumora reported $182.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
- R&D expenses decreased to $176.1 million in 2025 from $200.9 million in 2024, primarily due to reduced navacaprant-related costs.
- Net loss for full-year 2025 was $236.9 million, down slightly from $243.8 million in 2024.
- NMRA-511 showed a Cohen’s d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in a pre-specified Alzheimer’s agitation population.
- KOASTAL-2 and -3 trials for navacaprant are fully enrolled, with topline data expected in Q2 2026.
- NMRA-898 has been selected as the lead M4 program based on favorable Phase 1 pharmacokinetics and target engagement data.
- A 13-week rat toxicology study for NMRA-215 revealed unexpected adverse findings in 5 of 142 animals; Neumora is repeating the study and delaying clinical initiation to Q1 2027.
Financial Impact
Reduced R&D spending by $24.8M YoY contributed to lower net loss. Cash runway extended into Q3 2027.
Risk Factors
- Unexpected toxicology findings in NMRA-215 could signal safety issues or development challenges.
- Clinical data for navacaprant and NMRA-511 remain upcoming; failure to meet endpoints could negatively impact valuation.
- Biotech sentiment and financing conditions may affect future capital raising if extended runway is needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264464 |
Track record
14 reports on NMRA
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers